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1  | INTRODUC TION
Rheumatoid arthritis (RA) is a common chronic inflammatory disease 
in synovial joints, which has affected up to 1% of the adult popula‐
tion worldwide. However, the etiology of RA remains unclear. Many 
studies have found the role of some interleukins (ILs) in the patho‐
genesis of RA. For example, IL‐1beta plays a key role in human RA 
synovial fibroblasts through inducing intercellular adhesion mole‐
cule (ICAM)‐1 expression and enhancing leukocyte adhesion.1 IL‐10 
is associated with disease activity through the production of lym‐
phocyte‐activation gene 3 + regulatory T cells.2 In this study, we pay 
close attention to IL‐6. IL‐6 is a multifunctional cytokine involved 
in the inflammatory response. The overexpression of IL‐6 in tissues 
of RA patients may be associated with the pathogenesis of RA.3,4 
Moreover, Schinnerling et al reported that IL‐6 was associated with 
the differentiation of Th17 cells and the balance between patho‐
genic Th17 and protective Treg in RA.5 Thus, IL‐6 may play key roles 
in the pathogenesis of RA.
Currently, many studies on twins and families have been per‐
formed and found RA has some genetic factors.6‐8 The genetic sus‐
ceptibility to RA has been found to be associated with many genes, 
such as chemokine ligand 3‐like 1 (CCL3L1) gene, programmed death 
1 gene, tumor necrosis factor α (TNFα) gene and IL genes.9‐13 Some 
studies have confirmed the potential association between IL‐6 gene 
polymorphisms	(including	−174	G/C	and	−572	G/C)	and	RA	suscepti‐
bility.14‐17 Some meta‐analyses have been conducted and confirmed 
IL‐6	−174	G/C	polymorphism	confers	susceptibility	to	RA.18,19 Young 
Ho	Lee	et	al	also	investigated	the	IL‐6	−572	G/C	polymorphism	with	
only two studies, which did not provide enough evidence on the 
association	between	 IL‐6	−572	G/C	polymorphism	and	 risk	of	RA.	
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Abstract
Aims: This	meta‐analysis	was	aimed	to	investigate	the	association	between	−572G/C	
interleukin (IL)‐6 gene polymorphism and occurrence risk of rheumatoid arthritis 
(RA).
Methods: Literature	search	was	conducted	in	PubMed,	Embase,	Springer	and	Google	
Scholar up to November 2018. The pooled odds ratios (ORs) and 95% confidence 
interval (CI) were calculated by Revman 5.3.
Results: A total of six case‐control studies were included in this meta‐analysis. In the 
allele	model	(G	vs	C),	homozygous	gene	model	(GG	vs	CC),	recessive	gene	model	(GG	
vs	GC	+	CC),	and	dominant	gene	model	(GG	+	GC	vs	CC),	the	pooled	estimate	indi‐
cated	there	was	significant	association	between	−572G/C	IL‐6	gene	polymorphism	
and risk of RA. However, no significant statistical results were found in meta‐analy‐
ses of heterozygote gene models.
Conclusions: The	−572G/C	IL‐6	gene	polymorphism	is	associated	with	the	risk	of	RA.	
The	GG	genotype	may	be	the	main	contributor	in	increasing	susceptibility	to	RA.
K E Y W O R D S
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48  |     ZHANG et Al.
Recently,	IL‐6	−572	G/C	polymorphism	has	been	investigated	in	RA	
patients.17,19‐23 Thus, we performed this meta‐analysis to further 
confirm	the	relationship	between	−572	G/C	IL‐6	gene	polymorphism	
and risk of RA.
2  | MATERIAL S AND METHODS
2.1 | Search strategy
We conducted a literature search on databases including PubMed, 
Embase,	Springer	and	Google	Scholar	with	the	end‐date	of	February	
2019. The key words included: (“Rheumatoid” OR “Rheumatoid 
arthritis”)	 AND	 (“572G/C”	OR	 “rs1800796”	OR	 “Interleukin	 6”	OR	
“IL‐6”) AND “polymorphism”. We also manually scanned the refer‐
ence lists of some relevant reviews to obtain additional studies.
2.2 | Inclusion and exclusion criteria
The inclusion criteria in this meta‐analysis were: (a) studies were 
case‐control studies; (b) participants were patients with RA and 
controls	 (healthy	 controls);	 (c)	 −572	 G/C	 IL‐6	 gene	 polymorphism	
(rs1800796)	was	detected;	 (d)	the	frequencies	of	alleles	 (G,	C)	and	
genotypes	 (GG,	 GC,	 CC)	 were	 reported	 or	 could	 be	 obtained	 by	
calculation.
Exclusion criteria were: (a) non‐original articles (such as letters, 
comments or reviews); (b) no available data; (c) duplicated publi‐
cations (only studies with complete data could be included in this 
meta‐analysis).
2.3 | Quality assessment and data extraction
The quality of included studies was assessed independently by two 
investigators. Different evaluation results were resolved by discus‐
sion to ensure consistency of evaluation. The extracted data were 
recorded using a predesigned form including: first author name, 
publication year, study location, age, gender, sample size, method of 
detecting polymorphisms, and outcomes.
The quality of these included case‐control studies was evaluated 
by the Newcastle‐Ottawa Scale (NOS),24 which is comprised of three 
key domains and eight questions (selection: total four questions, one 
score assigned to each question; comparison: total one question, 
two scores assigned to this question; explore: total three questions, 
one score assigned to each question). Thus, a total of nine scores 
can be obtained. Studies with less than five scores was regarded as 
low‐quality by NOS in this meta‐analysis.
2.4 | Statistical analysis
All analyses were performed using Revman 5.3. Hardy–Weinberg 
equilibrium was tested in controls by a χ2 test.25 The allele model 
(G	 vs	C),	 homozygous	 gene	model	 (GG	vs	CC),	 heterozygote	 gene	
models	(GG	vs	GC,	GC	vs	CC),	recessive	gene	model	(GG	vs	GC	+	CC)	
and	dominant	gene	model	(GG	+	GC	vs	CC)	were	used	to	evaluate	
the	association	between	−572	G/C	IL‐6	gene	polymorphism	and	RA.	
The χ2 and I2 tests were used to evaluate the heterogeneity across 
included studies. The presence of significant statistical heterogene‐
ity of outcomes across included studies was assessed when P < .05 
and I2 > 50%. If there was no significant heterogeneity (P value for 
heterogeneity	≥.05	or	I2	≤	50%),	a	fixed‐effects	model	was	chosen	
to pool the effect size; otherwise, a random‐effects model was use. 
The pooled odds ratios (ORs) as well as their 95% confidence inter‐
val (CI) was used. In addition, sensitivity analysis was performed by 
omitting one study at a time. Subgroup analyses were performed by 
country. Publication bias was assessed by Egger's test.
3  | RESULTS
3.1 | Characteristics of included studies
Literature search and study selection processes are shown in 
Figure 1. The initial literature search on databases identified 363 
articles. After excluding duplicates, 79 potentially relevant articles 
remained. Afterward, 50 irrelevant articles were excluded by scan‐
ning titles or reading the full text. Among them, 13 studies which did 
not	report	−572	G/C	IL‐6	gene	polymorphism	were	excluded,	 four	
studies were eliminated because of no available data, and six reviews 
were excluded. No additional studies were found by manual search. 
Finally, six articles17,19‐23 were included in this meta‐analysis.
The characteristics of the 6 included studies are listed in Table 1. 
The publication year ranged from 2007 to 2016. In the six included 
case‐control studies, a total of 1241 RA patients and 1320 con‐
trols were reanalyzed in this meta‐analysis. Three studies were 
conducted in China and the other three studies were conducted in 
Turkey, Egypt and Mexico, respectively. All these studies detected 
the	 −572	G/C	 IL‐6	 gene	 polymorphism	by	PCR	 (polymerase	 chain	
reaction) only or PCR amplification and high resolution melt anal‐
ysis.	The	−572	G/C	IL‐6	gene	polymorphism	of	the	controls	in	each	
included study met the Hardy–Weinberg equilibrium (Table 1). In ad‐
dition, based on NOS, no low‐quality studies were included in this 
meta‐analysis (Table 2).
F I G U R E  1   Flow diagram of the study selection process
     |  49ZHANG et Al.
TA
B
LE
 1
 
C
ha
ra
ct
er
is
tic
s 
of
 in
cl
ud
ed
 s
tu
di
es
A
ut
ho
r, 
y
Co
un
tr
ie
s
So
ur
ce
 o
f c
on
tr
ol
G
ro
up
Sa
m
pl
e 
si
ze
G
en
de
r, 
F/
M
A
ge
, m
ea
n,
 y
A
lle
le
s,
 G
/C
G
en
ot
yp
e 
fr
e‐
qu
en
ci
es
, G
G
/
G
C/
CC
P H
W
E f
or
 
co
nt
ro
l
G
en
ot
yp
in
g 
m
et
ho
d
A
rm
an
 (2
01
2)
21
Tu
rk
ey
H
ea
lth
y 
co
nt
ro
l
R
A
17
8
14
9/
29
53
.1
2 
± 
12
.7
31
7/
39
14
3/
31
/4
>.
05
PC
R 
on
ly
C
on
tr
ol
24
7
16
0/
87
54
.3
 ±
 1
1.
8
44
0/
54
19
4/
52
/1
K
ha
ld
a 
A
m
r 
(2
01
6)
20
Eg
yp
t
H
ea
lth
y 
Eg
yp
tia
n 
su
bj
ec
ts
 w
ith
 
no
 fa
m
ily
 h
is
to
rie
s 
of
 a
ny
 
au
to
im
m
un
e 
di
se
as
es
R
A
99
90
/9
N
A
11
6/
82
26
/6
4/
9
>.
05
PC
R 
on
ly
C
on
tr
ol
99
58
/4
1
13
0/
68
36
/5
8/
5
Fe
ng
 L
i 
(2
01
4)
19
C
hi
na
H
ea
lth
y 
co
nt
ro
ls
 fr
om
 th
e 
sa
m
e 
ge
og
ra
ph
ic
 a
nd
 e
th
ni
c 
ba
ck
gr
ou
nd
R
A
25
6
N
A
N
A
17
1/
34
1
23
/1
25
/1
08
>.
05
PC
R 
am
pl
ifi
ca
‐
tio
n 
an
d 
H
RM
 
an
al
ys
is
C
on
tr
ol
33
1
23
4/
42
8
41
/1
52
/1
38
Za
va
le
ta
‐M
uñ
iz
 
(2
01
3)
17
M
ex
ic
o
H
ea
lth
y 
su
bj
ec
ts
 in
 a
 s
im
ila
r 
ag
e 
ra
ng
e 
w
er
e 
se
le
ct
ed
 a
s 
co
nt
ro
ls
R
A
13
7
13
5/
2
50
 ±
 9
20
6/
68
74
/5
8/
5
>.
05
PC
R 
on
ly
C
on
tr
ol
10
2
96
/6
48
 ±
 1
0
16
1/
43
62
/3
7/
3
C
ho
ng
‐g
e 
Yo
u 
(2
01
2)
22
C
hi
na
Th
e 
co
nt
ro
ls
 w
er
e 
et
hn
ic
al
ly
 
an
d 
ge
og
ra
ph
ic
al
ly
 m
at
ch
ed
 
he
al
th
y 
su
bj
ec
ts
 w
ith
ou
t R
A
 
fa
m
ily
 h
is
to
ry
 ta
ke
n 
fr
om
 
in
di
vi
du
al
 c
he
ck
up
s
R
A
45
1
N
A
N
A
26
7/
63
5
38
/1
91
/2
22
>.
05
PC
R 
am
pl
ifi
ca
‐
tio
n 
an
d 
H
RM
 
an
al
ys
is
C
on
tr
ol
37
3
24
4/
50
2
39
/1
66
/1
68
H
ua
ng
 (2
00
7)
23
C
hi
na
Th
e 
co
nt
ro
ls
 w
er
e 
et
hn
ic
al
ly
 
an
d 
ge
og
ra
ph
ic
al
ly
 m
at
ch
ed
 
he
al
th
y 
su
bj
ec
ts
 w
ith
ou
t R
A
 
fa
m
ily
 h
is
to
ry
 ta
ke
n 
fr
om
 
in
di
vi
du
al
 c
he
ck
up
s
R
A
12
0
10
0/
20
48
.4
8 
± 
14
.9
8
23
/2
17
4/
15
/1
01
>.
05
PC
R 
on
ly
C
on
tr
ol
16
8
10
1/
67
45
.1
8 
± 
8.
11
76
/2
60
13
/5
0/
10
5
A
bb
re
vi
at
io
ns
: H
RM
, h
ig
h 
re
so
lu
tio
n 
m
el
t; 
H
W
E,
 H
ar
dy
–W
ei
nb
er
g 
eq
ui
lib
riu
m
; N
A
, n
ot
 re
po
rt
ed
; P
C
R,
 p
ol
ym
er
as
e 
ch
ai
n 
re
ac
tio
n;
 R
A
, r
he
um
at
oi
d 
ar
th
rit
is
.
50  |     ZHANG et Al.
3.2 | Meta‐analysis for relationship between −572 
G/C IL‐6 gene polymorphism and RA
In	 the	 allele	 model	 (G	 vs	 C),	 significant	 heterogeneity	 (I2 = 59%, 
P = .03) among studies was observed, so the random‐effect model 
was used for meta‐analysis of the allele model. The results showed 
that	 high	 risk	 of	 RA	was	 significantly	 associated	with	 the	G	 allele	
of	 −572	G/C	 IL‐6	 gene	 polymorphism	 compared	with	 the	C	 allele	
(OR = 0.78, 95% CI = 0.63‐0.97, P = .03, Figure 2A).
In	the	homozygous	gene	model	(GG	vs	CC),	there	was	no	signif‐
icant heterogeneity among studies (I2 = 0%, P = .59), so the pooled 
data was calculated by the fixed‐effect model. The pooled data 
showed	significant	association	between	the	GG	genotype	of	−572	
G/C	IL‐6	gene	polymorphism	and	high	risk	of	RA	compared	with	the	
CC genotype (OR = 0.62, 95% CI = 0.45‐0.86, P = .004, Figure 2B).
In heterozygote gene models, no significant heterogeneity 
among studies (I2 = 0%, P = .59) was found when comparing the 
GG	genotype	with	 the	GC	genotype,	 so	 a	 fixed‐effect	model	was	
used. However, a random‐effect model was applied in meta‐analy‐
sis	of	GC	versus	CC	because	of	significant	heterogeneity	(I2 = 63%, 
P	=	.02).	The	results	of	meta‐analysis	indicated	that	the	GC	genotype	
was	not	significantly	associated	with	risk	of	RA	compared	with	GG	
(OR = 0.84, 95% CI = 0.67‐1.07, P = .15, Figure 2C) or CC (OR = 0.68, 
95% CI = 0.44‐1.06, P = .09, Figure 2D).
In	the	recessive	gene	model	(GG	vs	GC	+	CC),	no	significant	het‐
erogeneity among studies was found (I2 = 0%, P = .54). Thus, a fixed‐
effect model was applied to conduct a meta‐analysis of the recessive 
gene model. The pooled estimate indicated there was significant as‐
sociation	between	−572	G/C	IL‐6	gene	polymorphism	and	risk	of	RA	
(OR = 0.78, 95% CI = 0.62‐0.97, P = .03, Figure 2E).
In	the	dominant	gene	model	(GG	+	GC	vs	CC),	significant	hetero‐
geneity among studies was found (I2 = 64%, P = .02). Thus, a fixed‐ef‐
fect model was applied to conduct a meta‐analysis of the dominant 
gene model. The pooled estimate indicated there was significant as‐
sociation	between	−572	G/C	IL‐6	gene	polymorphism	and	risk	of	RA	
(OR = 0.78, 95% CI = 0.62‐0.97, P = .03, Figure 2F).
3.3 | Subgroup analyses
As shown in Table 3, only the studies conducted in China were ana‐
lyzed.	 In	 these	analyses,	only	 the	homozygous	gene	model	 (GG	vs	
CC)	and	recessive	gene	model	(GG	vs	GC	+	CC)	indicated	significant	
association	between	−572	G/C	IL‐6	gene	polymorphism	and	risk	of	
RA. Significant heterogeneity among studies still existed in the allele 
model	(G	vs	C),	heterozygote	gene	model	(GC	vs	CC),	and	dominant	
gene	model	(GG	+	GC	vs	CC).
3.4 | Sensitivity analyses and publication bias
In this study, sensitivity analyses showed the results of this meta‐
analysis were unstable. Inconsistent results with overall analyses are 
shown in Table 4. Egger's test showed there was no significant pub‐
lication bias (P > .05).TA
B
LE
 2
 
Re
su
lts
 o
f q
ua
lit
y 
as
se
ss
m
en
t u
si
ng
 N
O
S 
sc
al
e
St
ud
y
Se
le
ct
io
n
Co
m
pa
ra
bi
lit
y
Ex
po
su
re
To
ta
l
Is
 th
e 
ca
se
 
de
fin
iti
on
 
ad
eq
ua
te
? 
(to
ta
l 
sc
or
e:
 1
)
Re
pr
es
en
ta
tiv
en
es
s 
of
 th
e 
ca
se
s (
to
ta
l 
sc
or
e:
 1
)
Se
le
ct
io
n 
of
 c
on
tr
ol
s 
(to
ta
l s
co
re
: 
1)
D
ef
in
iti
on
 
of
 c
on
tr
ol
s 
(to
ta
l s
co
re
: 
1)
Co
m
pa
ra
bi
lit
y 
of
 
ca
se
s a
nd
 c
on
tr
ol
s o
n 
th
e 
ba
si
s o
f t
he
 d
es
ig
n 
or
 a
na
ly
si
s (
to
ta
l 
sc
or
e:
 2
)
A
sc
er
ta
in
m
en
t 
of
 e
xp
os
ur
e 
(to
ta
l s
co
re
: 1
)
Sa
m
e 
m
et
ho
d 
of
 a
sc
er
‐
ta
in
m
en
t f
or
 c
as
es
 a
nd
 
co
nt
ro
ls
 (t
ot
al
 s
co
re
: 1
)
N
on
‐r
e‐
sp
on
se
 ra
te
 
(to
ta
l s
co
re
: 
1)
A
rm
an
 (2
01
2)
21
1
1
0
1
1
1
1
1
7
C
ho
ng
‐g
e 
Yo
u 
(2
01
2)
22
1
1
1
1
1
1
1
1
8
Fe
ng
 L
i (
20
14
)19
1
1
1
1
1
1
1
1
8
H
ua
ng
 (2
00
7)
23
1
1
1
1
1
1
1
1
8
K
ha
ld
a 
A
m
r (
20
16
)2
0
1
1
0
1
1
1
1
1
7
Za
va
le
ta
‐M
uñ
iz
 (2
01
3)
17
1
1
1
1
1
1
1
1
8
A
bb
re
vi
at
io
n:
 N
O
S,
 N
ew
ca
st
le
‐O
tt
aw
a 
Sc
al
e.
     |  51ZHANG et Al.
F I G U R E  2   Overall meta‐analyses 
for	assessing	relationship	of	−572	
G/C	interleukin	6	promoter	gene	
polymorphisms (rs1800796) with 
rheumatoid arthritis risk
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4  | DISCUSSION
In	 this	 study,	we	 found	 significant	 association	between	−572	G/C	
IL‐6 gene polymorphism and risk of RA. Moreover, based on gene 
models,	we	found	the	G	allele	or	GG	genotype	were	significantly	as‐
sociated with high risk of RA, compared with the C allele or CC geno‐
type.	Although	the	meta‐analyses	of	the	recessive	gene	model	(GG	
vs	GC	+	CC)	and	dominant	gene	model	 (GG	+	GC	vs	CC)	 indicated	
significant statistical results, no significant association between 
−572	G/C	IL‐6	gene	polymorphism	and	risk	of	RA	was	found	in	the	
meta‐analyses of heterozygote gene models. Thus, we speculated 
that	the	GG	genotype	may	be	the	contributor	of	−572	G/C	IL‐6	gene	
to increasing RA susceptibility. The results of subgroup analyses also 
provided evidences for this speculation.
Some studies have explored the role of IL‐6 in pathogenesis of 
RA. In the study of Hwang et al, it showed that the overexpression 
of IL‐6 in RA was regulated by IL‐17 via nuclear factor (NF)‐kappaB‐ 
and PI3‐kinase/Akt‐dependent pathways.4 Lin et al found that Cyr61 
can induce the expression of IL‐6 in RA.26 It was reported Cyr61 
may play a key role in IL‐17‐dependent proliferation of fibroblast‐like 
synoviocytes in RA.27 As known, cell proliferation of fibroblast‐like 
synoviocytes is one of the main mechanisms associated with the oc‐
currence and development of RA. Moreover, it was reported that 
spontaneous activation of NF‐kappaB and CBF1 may be the contrib‐
utors inducing the constitutive transcription of the IL‐6 gene in rheu‐
matoid synoviocytes of RA.28 Thus, IL‐6 overexpression may play 
key roles in the occurrence and development of RA via the above 
potential	mechanisms.	The	GG	genotype	of	−572	G/C	polymorphism	
Subgroup Gene model
Test of relationship
Model
Test of 
heterogeneity
OR (95% CI) P P I2 (%)
China (includ‐
ing 3 studies)
G	vs	C 0.71 (0.48, 1.06) .09 R .003 82
GG	vs	CC 0.67 (0.47, 0.95) .02 F .41 0
GG	vs	GC 0.79 (0.55, 1.12) .19 F .78 0
GC	vs	CC 0.71 (0.42, 1.21) .21 R .004 82
GG	vs	GC	+	CC 0.70 (0.50, 0.99) .04 F .59 0
GG	+	GC	vs	CC 0.68 (0.40, 1.14) .14 R .003 83
Abbreviations: CI, confidence interval; F, fixed‐effect model; OR, odds ratio; R, random‐effect 
model.
TA B L E  3   Results of subgroup 
meta‐analysis
Gene model Omitted study
Test of relationship
Model
Test of het‐
erogeneity
OR (95% CI) P P I2 (%)
G	vs	C Chong‐ge You 
(2012)22
0.75 (0.55, 1.01) .06 R .02 67
Khalda Amr (2016)20 0.78 (0.60, 1.02) .06 R .02 67
GG	vs	GC Arman (2012)21 0.75 (0.58, 0.98) .04 F .94 0
GG	vs	GC	+	CC Chong‐ge You 
(2012)22
0.78 (0.60, 1.00) .05 F .40 1
Feng Li (2014)19 0.80 (0.62, 1.02) .07 F .43 0
Huang (2007)23 0.80 (0.64, 1.01) .06 F .59 0
Khalda Amr (2016)20 0.81 (0.63, 1.03) .08 F .49 0
Zavaleta‐Muñiz 
(2013)17
0.78 (0.61, 1.00) .05 F .40 1
GG	+	GC	vs	CC Arman (2012)21 0.68 (0.44, 1.03) .07 R .02 67
Chong‐ge You 
(2012)22
0.54 (0.27, 1.08) .08 R .01 69
Huang (2007)23 0.86 (0.70, 1.06) .16 F .51 0
Khalda Amr (2016)20 0.65 (0.41, 1.05) .08 R .01 70
Abbreviations: CI, confidence interval; F, fixed‐effect model; OR, odds ratio; R, random‐effct 
model.
TA B L E  4   Sensitivity analyses showing 
inconsistent results with overall analyses
     |  53ZHANG et Al.
in IL‐6 gene promoter may contribute to RA susceptibility by regulat‐
ing expression of the IL‐6 gene.
Some limitations of this meta‐analysis should be noted. First, the 
number of included studies and the sample size were small. Second, 
significant heterogeneity among studies was found in this meta‐
analysis. Although the subgroup analyses were performed, only the 
region was considered in this study due to not enough data on other 
confounding factors. Third, the sensitivity analyses showed the re‐
sults	 of	meta‐analyses	 on	 the	 allele	model	 (G	 vs	 C),	 heterozygote	
gene	model	(GG	vs	GC),	recessive	gene	model	(GG	vs	GC	+	CC)	and	
dominant	gene	model	(GG	+	GC	vs	CC)	were	unstable.	More	studies	
should be performed to provide more evidence on association be‐
tween	−572	G/C	IL‐6	gene	polymorphism	and	risk	of	RA.
5  | CONCLUSION
In	conclusion,	−572	G/C	IL‐6	gene	polymorphism	is	associated	with	
the	 risk	of	RA.	GG	genotype	may	be	 the	contributor	of	−572	G/C	
IL‐6 gene to increasing RA susceptibility. More studies are needed to 
further confirm the results of this meta‐analysis.
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